BioFactura, Inc.
http://www.biofactura.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioFactura, Inc.
Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
No US Filing Until 2026? Aurobindo’s CuraTeQ Inks Ustekinumab Deal
With J&J’s blockbuster Stelara treatment for autoimmune diseases scheduled to fall to biosimilar competition in the coming years, Aurobindo’s biosimilars business has stepped up to get a piece of the action, striking a deal with BioFactura.
History Repeats: Will US Stelara Settlements Follow Humira’s Lead?
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.
BioFactura’s Ustekinumab Biosimilar To Be Trialed As ‘Robotic’ Pill
BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Burrell International Group, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice